Generics - Asia-Pacific, Pfizer

Filter

Current filters:

Asia-PacificPfizer

Popular Filters

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

India's Cipla cuts prices of three cancer drugs

12-11-2012

Following what Indian drugmaker Cipla (BSE: 500087) said was an "overwhelming response" on the price…

Asia-PacificcapecitabineCipladocetaxelerlotinibGenericsOncologyPatentsPfizerPharmaceuticalPricingSunitinib MalateSutent

Another negative Indian patent ruling, this time for Pfizer's Sutent

08-10-2012

In yet another setback for research-based pharmaceutical companies, last week the Indian patent office…

Asia-PacificCiplaGenericsLegalNatco PharmaOncologyPatentsPfizerPharmaceuticalSutent

Pfizer launches generics JV in China with Hisun

14-09-2012

Global drugs behemoth Pfizer (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE Code: 600267), a leading…

Asia-PacificGenericsHisun-PfizerMergers & AcquisitionsPfizerPharmaceuticalZhejiang Hisun Pharma

Pfizer teams up with Mylan to drive generics business in Japan

23-08-2012

Global pharma behemoth Pfizer (NYSE: OFE) and generics drug major Mylan (Nasdaq: MYL) have signed a definitive…

Asia-PacificGenericsMarkets & MarketingMylan LaboratoriesPfizerProduction

Pfizer and Hisun flesh-out plans for generics JV in China

19-02-2012

Global drugs behemoth Pfizer (NYSE: PFE) and Zhejiang Hisun Pharmaceutical (SSE Code: 600267), a leading…

Asia-PacificGenericsMergers & AcquisitionsPfizerZhejiang Hisun Pharma

Back to top